12
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Severe malnutrition accounts for half-a-million deaths annually in children under the age of five. Despite improved WHO guidelines, inpatient mortality remains high and is associated with metabolic dysfunction. Previous studies suggest a correlation between hepatic metabolic dysfunction and impaired autophagy. We aimed to determine the role of mTORC1 inhibition in a murine model of malnutrition-induced hepatic dysfunction. Wild type weanling C57/B6 mice were fed a 18 or 1% protein diet for two weeks. A third low-protein group received daily rapamycin injections, an mTORC1 inhibitor. Hepatic metabolic function was assessed by histology, immunofluorescence, gene expression, metabolomics and protein levels. Low protein-fed mice manifested characteristics of severe malnutrition, including weight loss, hypoalbuminemia, hypoglycemia, hepatic steatosis and cholestasis. Low protein-fed mice had fewer mitochondria and showed signs of impaired mitochondrial function. Rapamycin prevented hepatic steatosis, restored ATP levels and fasted plasma glucose levels compared to untreated mice. This correlated with increased content of LC3-II, and decreased content mitochondrial damage marker, PINK1. We demonstrate that hepatic steatosis and disturbed mitochondrial function in a murine model of severe malnutrition can be partially prevented through inhibition of mTORC1. These findings suggest that stimulation of autophagy could be a novel approach to improve metabolic function in severely malnourished children.

          Related collections

          Most cited references65

          • Record: found
          • Abstract: found
          • Article: found

          Maternal and child undernutrition and overweight in low-income and middle-income countries

          The Lancet, 382(9890), 427-451
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            mTOR signaling in growth control and disease.

            The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis. The pathway regulates many major cellular processes and is implicated in an increasing number of pathological conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration. Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging. We further discuss pharmacological approaches to treat human pathologies linked to mTOR deregulation. Copyright © 2012 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              AKT/PKB Signaling: Navigating the Network

              The Ser/Thr kinase AKT, also known as protein kinase B (PKB), was discovered 25 years ago and has been the focus of tens of thousands of studies in diverse fields of biology and medicine. There have been many advances in our knowledge of the upstream regulatory inputs into AKT, key multifunctional downstream signaling nodes (GSK3, FoxO, mTORC1), which greatly expand the functional repertoire of Akt, and the complex circuitry of this dynamically branching and looping signaling network that is ubiquitous to nearly every cell in our body. Mouse and human genetic studies have also revealed physiological roles for the AKT network in nearly every organ system. Our comprehension of AKT regulation and functions is particularly important given the consequences of AKT dysfunction in diverse pathological settings, including developmental and overgrowth syndromes, cancer, cardiovascular disease, insulin resistance and type-2 diabetes, inflammatory and autoimmune disorders, and neurological disorders. There has also been much progress in developing AKT-selective small molecule inhibitors. Improved understanding of the molecular wiring of the AKT signaling network continues to make an impact that cuts across most disciplines of the biomedical sciences.
                Bookmark

                Author and article information

                Contributors
                robert.bandsma@sickkids.ca
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                19 November 2022
                19 November 2022
                2022
                : 12
                : 19948
                Affiliations
                [1 ]GRID grid.42327.30, ISNI 0000 0004 0473 9646, Translational Medicine Program, , Hospital for Sick Children, ; Toronto, Canada
                [2 ]GRID grid.4494.d, ISNI 0000 0000 9558 4598, Department of Pediatrics, Section of Molecular Metabolism and Nutrition, , University Medical Center Groningen, ; Groningen, The Netherlands
                [3 ]GRID grid.511677.3, The Childhood Acute Illness and Nutrition Network, ; Nairobi, Kenya
                [4 ]GRID grid.17063.33, ISNI 0000 0001 2157 2938, Department of Nutritional Sciences, Faculty of Medicine, , University of Toronto, ; Toronto, Canada
                [5 ]GRID grid.17063.33, ISNI 0000 0001 2157 2938, Department of Biochemistry, Faculty of Medicine, , University of Toronto, ; Toronto, Canada
                [6 ]GRID grid.42327.30, ISNI 0000 0004 0473 9646, Cell Biology Program, , Hospital for Sick Children, ; Toronto, Canada
                [7 ]GRID grid.42327.30, ISNI 0000 0004 0473 9646, Centre for Global Child Health, , Hospital for Sick Children, ; Toronto, Canada
                Article
                24428
                10.1038/s41598-022-24428-7
                9675758
                36402829
                898c26c1-dd3a-4402-a8f9-c19a5898192f
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 24 June 2021
                : 15 November 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001721, Rijksuniversiteit Groningen;
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award ID: 156307
                Award ID: 156307
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                preclinical research,nutrition,paediatric research,autophagy
                Uncategorized
                preclinical research, nutrition, paediatric research, autophagy

                Comments

                Comment on this article